[Caracterización de nuevos genes implicados en metástasis en cáncer de próstata]
Bary Bigay Mercedes1, Katlin De La Rosa Poueriet1
1. ChromoMed Institute, Santo Domingo, Dominican Republic.
Keywords:
prostate cancer, BRCA1, BRCA2, androgenic repector, PTEN
DOI: 10.37980/im.journal.ggcl.20242330
Published: 2024-08-31
Introduction: Our work addresses a literature review conducted between January 2019 and September 2023, the importance of BRCA1, BRCA2, AR and PTEN genes in the pathogenesis, prognosis and treatment of prostate cancer, especially in its metastatic castration-resistant form (mCRPC), is highlighted. BRCA1 and BRCA2 genes are identified as key markers for predicting cancer aggressiveness, suggesting the need for targeted therapies and strict surveillance. The adaptability of cancer cells and variability in androgen receptor (AR) expression limit the effectiveness of therapies focused solely on AR, pointing to the importance of identifying alternative pathways and biomarkers for more effective treatment. PTEN function is directly related to disease progression, and its alteration suggests potential therapeutic approaches. However, the heterogeneity of cancer cells and complexity of molecular pathways present significant challenges to the development of universal therapies. Conclusion: The findings promote future research to confirm the applicability of these genes as biomarkers and to develop personalized treatment strategies in prostate cancer.